替比夫定联合阿德福韦酯与PEG-IFN联合恩替卡韦治疗慢性乙型肝炎的效果比较

李娜; 苟卫; 崔伟丽

doi:10.3969/j.issn.1001-5256.2016.09.015

替比夫定联合阿德福韦酯与PEG-IFN联合恩替卡韦治疗慢性乙型肝炎的效果比较

DOI: 10.3969/j.issn.1001-5256.2016.09.015

青岛市第六人民医院肝病科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3115
- HTML全文浏览量: 35
- PDF下载量: 439
- 被引次数: 0
出版历程
- 出版日期: 2016-09-20

Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis

Department of Hepatology, The Sixth People′s Hospital of Qingdao

摘要

摘要: 目的观察替比夫定联合阿德福韦酯与PEG-IFNα-2a联合恩替卡韦治疗HBe Ag阳性的高病毒载量的慢性乙型肝炎患者的疗效差异。方法选取2012年11月-2015年11月在青岛市第六人民医院就诊的HBe Ag阳性、高病毒载量的慢性乙型肝炎初治患者共80例,随机分成两组,每组40例。A组为替比夫定联合阿德福韦酯抗病毒组,B组为PEG-IFNα-2a联合恩替卡韦抗病毒组。观察两组患者分别服药12、24、48周时生化学、病毒学及血清学转换率有无差异。观察两组患者病毒耐药率及不良反应发生情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果两组患者在12、24、48周时病毒学、生化学应答率差异均无统计学意义（P值均>0.05）。12、24周时两组血清学转换率无明显差异,而48周时B组HBe Ag阴转率及血清学转换率均高于A组且差异均有统计学意义（45.0%vs 67.5%,22.5%vs 45.0%,χ2值分别为4.114 3、4.528 3,P值均<0.05）。B组患者出现的不良反应高于A组。结论 PEG-IFNα-2a联...
- 肝炎,乙型,慢性 /
- 替比夫定 /
- 阿德福韦酯 /
- 干扰素类 /
- 恩替卡韦
Abstract: Objective To investigate the efficacy of telbivudine combined with adefovir dipivoxil and PEG- IFN- α- 2a combined with entecavir as the antiviral therapy for HBe Ag- positive patients with chronic hepatitis B( CHB) and a high viral load. Methods A total of 80 previously untreated HBe Ag- positive CHB patients with a high viral load who were treated in The Sixth People's Hospital of Qingdao from November2012 to November 2015 were enrolled and randomly divided into two groups. The patients in group A were treated with telbivudine combined with adefovir dipivoxil,and those in group B were treated with PEG- IFN- α- 2a combined with entecavir. Biochemical and virologic response rates and seroconversion rate were observed at weeks 12,24,and 48 of administration. The drug resistance rate and incidence rates of adverse events were observed in both groups. The Chi- square test was applied for comparision of categorical data between the two groups,and the t- test was applied for comparision of continuous data between the two groups. Results Biochemical and virologic response rates at weeks 12,24,and 48 of administration showed no significant differences between the two groups. The seroconversion rates at weeks 12 and 24 of administration showed no significant differences between the two groups,while at week 48 of administration,group B had significantly higher HBe Ag clearance rate and seroconversion rate than group A( 45. 0% vs 67. 5%,22. 5% vs 45. 0%,χ2= 4. 114 3 and 4. 528 3,both P < 0. 05). Group B had significantly higher incidence rates of adverse events than group A. Conclusion Telbivudine combined with adefovir dipivoxil and PEG- IFN- α- 2a combined with entecavir can effectively inhibit the replication of high- load HBV DNA,delay disease progression,and realize HBe Ag seroconversion. However,the two regimens have their own advantages and disadvantages and should be selected according to clinical situation.
- hepatitis B,chronic /
- telbivudine /
- adefovir dipivoxil /
- interferons /
- entecavir

HTML全文

参考文献(12)

[1] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].Chin J Intern Med,2011,50(2):168-179.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010版)[J].中华内科杂志,2011,50(2):168-179.

[2]CHANG TT,GISH RG,de MAN R,et al.A comparison of entecavir and lamivudine for HBe Ag-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001-1010.

[3]STELMA F,JANSEN L,SINNIGE MJ,et al.HLA-C and KIR combined genotype as new response marker for HBe Ag-positive chronic hepatitis B patients treated with interferon-based combination therapy[J].J Viral Hepat,2016.[Epub ahead of print]

[4]LI Q,ZHUO QB,HUANG YX,et al.Combination therapy and sequential therapy with interferons and nucleos(t)ide analogues against HBV[J].J Clin Hepatol,2015,31(4):495-499.(in Chinese)李强,卓其斌,黄玉仙,等.干扰素与核苷和核苷酸类药物联合或序贯治疗慢性乙型肝炎方案的探讨[J].临床肝胆病杂志,2015,31(4):495-498.

[5]TANG ZX.Modern application and evaluation of interferons in viral hepatitis[J].Int J Virol,2008,15(3):86-91.(in Chinese)唐振祥.干扰素类药物在病毒性肝炎中的现代应用与评价[J].国际病毒学杂志,2008,15(3):86-91.

[6]SHI YY.Clinical efficacy of long-acting interferon and conventional interferon in treatment of chronic hepatitis B:a comparative analysis of 60 cases[J].Med Forum,2015,19(5):640-642.(in Chinese)史媛媛.长效干扰素与常规干扰素治疗慢性乙肝60例临床对比观察[J].基层医学论坛,2015,19(5):640-642.

[7]SUN HY,WANG M,ZHANG SQ.Efficacy of telbivudine combined with adefovir dipivoxil or entecavir alone in treatment of patients with HBe Ag-positive hepatitis B:a comparative analysis[J].Inner Mongolia J Tradit Chin Med,2013,10(6):1-2.(in Chinese)孙海英,王明,张淑芹.替比夫定联合阿德福韦酯与单用恩替卡韦治疗HBe Ag阳性乙型病毒性肝炎疗效比较[J].内蒙古中医药,2013,10(6):1-2.

[8]MAO HG.Comparison of the effects between telbivudine with adefovir and entecavir in HBe Ag-positive chronic hepatidis B treatment[J].Chin J Microecol,2012,24(9):829-831.(in Chinese)毛惠国.替比夫定联合阿德福韦酯与恩替卡韦治疗HBe Ag阳性慢性乙型肝炎患者疗效比较[J].中国微生态学杂志,2012,24(9):829-831.

[9]HUANG SW,LIU BR,CHEN MS,et al.Establishmend of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine[J].J Clin Hepatol,2016,32(7):1287-1291.(in Chinese)黄水文,刘宝荣,陈明胜,等.替比夫定初治慢性乙型肝炎患者早期病毒学应答预测模型的建立[J].临床肝胆病杂志,2016,32(7):1287-1291.

[10]YUEN MF,FONG DY,WONG DK,et al.Hepatitis B virus DNA levels at week 4 of larnivudine treatment predict the 5-year ideal response[J].Hepatology,2007,46(6):1695-1703.

[11]LIU HX,LEI D.Efficacy of long-acting interferon combined with entecavir in treatment of chronic hepatitis B patients with poor response to adefovir dipivoxil[J].J Clin Intern Med,2015,32(10):707-709.(in Chinese)刘红霞,雷玎.长效干扰素联合恩替卡韦治疗阿德福韦酯应答不佳慢性乙型肝炎患者的疗效观察[J].临床内科杂志,2015,32(10):707-709.

[12]YOU Y,XIAO JH,LIAO Y,et al.Research advances in the antiviral mechanism of interferon[J].Guangdong Med J,2014,35(11):1795-1797.(in Chinese)游艳,肖建华,廖勇,等.干扰素抗病毒作用机制的研究进展[J].广东医学,2014,35(11):1795-1797.

施引文献

资源附件(0)

访问统计